TNFSF9 and neoplasm: Notably, TNFSF9 (CD137L) is a key activating immune checkpoint molecule, and its agonist, in combination with PD-L1, can potently activate and expand tumor-specific cytotoxic T cells, thereby enhancing their inhibitory and lethal effects on tumors (24).